This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case
Go to paperABSTRACT: …

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cell therapy: European legal and regulatory implications
Go to paperABSTRACT: This paper reviews some of the legal and regulatory considerations that may a…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Bioterrorism and bioethics: Challenges for industry, government and society
Go to paperABSTRACT: The emerging threat of bioterrorism raises important chall…

This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s

I have been struggling to understand the utility of Google Glass in most of the presented use cases. The Google Glass

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ATMP in practice: Towards a new industry landscape in tissue engineering
Go to paperABSTRACT: Regulatory divergences and market fragmentation across member…

The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers:

New books from the publisher of the Journal of CommercialBiotechnology

Biomedical and health entrepreneurship continues to expand around the world. Driven by global pressures to optimize the allocation of scarce resources, life science bioentrepreneurs are creating innovative products, platforms, service and systems that …

The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation.